ID   HL-60/MX2
AC   CVCL_3333
SY   HL-60/MX-2; HL60/MX2
DR   BTO; BTO:0003571
DR   CLO; CLO_0003782
DR   ATCC; CRL-2257
DR   cancercelllines; CVCL_3333
DR   ChEMBL-Cells; CHEMBL4295458
DR   ChEMBL-Targets; CHEMBL4296431
DR   LINCS_LDP; LCL-1083
DR   PubChem_Cell_line; CVCL_3333
DR   Wikidata; Q54889806
RX   PubMed=2568172;
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (ATCC=CRL-2257).
CC   Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC=CRL-2257
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 8,11
ST   D16S539: 11
ST   D18S51: 14
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 12,13
ST   FGA: 22,24
ST   Penta D: 10,12
ST   Penta E: 13,14
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3332 ! HL-60/MX1
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   PubMed=2568172;
RA   Harker W.G., Slade D.L., Dalton W.S., Meltzer P.S., Trent J.M.;
RT   "Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in
RT   the absence of P-glycoprotein overexpression.";
RL   Cancer Res. 49:4542-4549(1989).
//